JAK2 and essential thrombocythemia: Recently, Janus kinase 2 (JAK2) V617F mutation was detected in most of the patients with PV and about half of the patients with ET and PMF, leading to constitutive activation of Janus kinase-signal transducer and activator of transcription (JAK/STAT) signalling [3, 4].